S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:VVOS

Vivos Therapeutics (VVOS) Stock Price, News & Analysis

$4.83
+0.18 (+3.87%)
(As of 03/28/2024 ET)
Today's Range
$4.31
$4.85
50-Day Range
$4.26
$7.55
52-Week Range
$2.73
$48.79
Volume
113,892 shs
Average Volume
117,388 shs
Market Capitalization
$6.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
VVOS stock logo

About Vivos Therapeutics Stock (NASDAQ:VVOS)

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.

VVOS Stock Price History

VVOS Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Vivos Therapeutics announces women-led airway health event
Why Is Vivos Therapeutics (VVOS) Stock Down 35% Today?
Why Is Vivos Therapeutics (VVOS) Stock Up 290% Today?
See More Headlines
Receive VVOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/28/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:VVOS
Fax
N/A
Employees
154
Year Founded
N/A

Profitability

Net Income
$-23,840,000.00
Net Margins
-106.28%
Pretax Margin
-106.27%

Debt

Sales & Book Value

Annual Sales
$16.02 million
Book Value
$4.80 per share

Miscellaneous

Free Float
1,204,000
Market Cap
$6.30 million
Optionable
Optionable
Beta
8.04
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives


VVOS Stock Analysis - Frequently Asked Questions

How have VVOS shares performed in 2024?

Vivos Therapeutics' stock was trading at $12.44 at the beginning of the year. Since then, VVOS stock has decreased by 61.2% and is now trading at $4.83.
View the best growth stocks for 2024 here
.

When is Vivos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our VVOS earnings forecast
.

How were Vivos Therapeutics' earnings last quarter?

Vivos Therapeutics, Inc. (NASDAQ:VVOS) issued its earnings results on Monday, November, 15th. The company reported ($6.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.00) by $2.50. The company had revenue of $4.55 million for the quarter, compared to analyst estimates of $4.50 million. Vivos Therapeutics had a negative trailing twelve-month return on equity of 508.27% and a negative net margin of 106.28%.

When did Vivos Therapeutics' stock split?

Vivos Therapeutics's stock reverse split before market open on Friday, October 27th 2023. The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Vivos Therapeutics IPO?

Vivos Therapeutics (VVOS) raised $20 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 3,300,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners served as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers.

Who are Vivos Therapeutics' major shareholders?

Vivos Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Strategic Wealth Investment Group LLC (9.68%), Armistice Capital LLC (4.29%), Vanguard Group Inc. (0.80%), Vanguard Group Inc. (0.79%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bradford K Amman and Ronald Kirk Huntsman.
View institutional ownership trends
.

How do I buy shares of Vivos Therapeutics?

Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VVOS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners